Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Study efficacy measures will include the expression of dystrophin protein and motor function.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
To enable company to be future-ready by tapping potential in CDMO space
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Subscribe To Our Newsletter & Stay Updated
